| Patents for A61P 11 - Drugs for disorders of the respiratory system (87,767) |
|---|
| 09/18/2003 | WO2003075834A2 Activated protein c formulations |
| 09/18/2003 | WO2003075827A2 Use of mycobacterium w in the treatment of asthama(obstructive lung disease) |
| 09/18/2003 | WO2003075826A2 Process for manufacturing pharmaceutical composition comprises of mycobacterium w in the treatment of asthma(obstructive lung disease) |
| 09/18/2003 | WO2003075824A2 Process of manufacturing pharmaceutical composition useful for management of tuberculosis |
| 09/18/2003 | WO2003075741A2 METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE |
| 09/18/2003 | WO2003075685A2 Bioavailability/bioefficacy enhancing activity of cuminum cyminum and extracts and fractions thereof |
| 09/18/2003 | WO2003075670A1 Treatment and prevention of inflammatory disorders |
| 09/18/2003 | WO2003059252A3 Use of a novel cell surface protease from group b streptococcus |
| 09/18/2003 | WO2003053915A3 Compounds for the treatment of inflammatory disorders |
| 09/18/2003 | WO2003053368A3 Chalcone derivatives and their use to treat diseases |
| 09/18/2003 | WO2003048122A3 Inhibitors of cytosolic phospholipase a2 |
| 09/18/2003 | WO2003035007A3 Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2 |
| 09/18/2003 | WO2003032928A3 Therapeutic composition and use |
| 09/18/2003 | WO2003011274A3 Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma |
| 09/18/2003 | WO2002083700B1 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations |
| 09/18/2003 | WO2002066646A3 Neurotransmission-associated proteins |
| 09/18/2003 | WO2002062750A9 Cannabinoid receptor ligands |
| 09/18/2003 | WO2002059308A3 Method of diagnosing and treating cartilage disorders |
| 09/18/2003 | WO2002050287A3 Multifunctional protease inhibitors and their use in treatment of disease |
| 09/18/2003 | US20030176726 Selective retinoid agonists |
| 09/18/2003 | US20030176695 Such as N-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-2-methyl-isonicotinamide for treatment of disorders of the central nervous system; neuroprotectants |
| 09/18/2003 | US20030176686 Diagnosis, therapy; animal growth regulators; controlling cell differentiation; antiiinflammatory agents, antihistamines, Crohn's disease, anticancer agents, autoimmune disease |
| 09/18/2003 | US20030176642 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors |
| 09/18/2003 | US20030176509 Methods and products related to 16-HETE analogs |
| 09/18/2003 | US20030176498 Inhibitors of alpha4mediated cell adhesion |
| 09/18/2003 | US20030176497 Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments |
| 09/18/2003 | US20030176496 Administering an antiproliferative agent in combination with a potentiating effective amount of a N- substituted dithiocarbamate ester or a pharmaceutically acceptable salt thereof |
| 09/18/2003 | US20030176491 For therapy and prophylaxis of prostatitis or interstitial cystitis, inflammatory bowel disease, Crohn's disease, ulcerative proctitis, or colitis, prostatic hypertrophy, uterine leiomyomas, breast cancer, endometrial cancer |
| 09/18/2003 | US20030176481 Novel imidazole derivatives with anti-inflammatory activity |
| 09/18/2003 | US20030176460 Piperidine compounds for use as ccr-3 inhibitors |
| 09/18/2003 | US20030176455 Inhibiting cell death following cellular regeneration in a mammal in need thereof, which comprises providing with an effective amount of a rapamycin |
| 09/18/2003 | US20030176446 2,2-disubstituted 1,3-dioxolanes as antitussive agents |
| 09/18/2003 | US20030176445 Substituted 1,4-dihydropyridine compounds as bradykinin antagonists |
| 09/18/2003 | US20030176441 Inhibitsthe binding of eotaxin to the CCR-3 receptor and thereby provide a means of combating eosinophil induced diseases, such as asthma |
| 09/18/2003 | US20030176437 Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death |
| 09/18/2003 | US20030176430 For therapy and prophylaxis of Tachykinin-mediated diseases |
| 09/18/2003 | US20030176422 Pyridoarylphenyl oxazolidinone antibacterials, and related compositions and methods |
| 09/18/2003 | US20030176420 Treatment of T-helper cell type 2-mediated immune diseases by retinoid antagonists |
| 09/18/2003 | US20030176416 For therapy of disease, disorder or condition is responsive to modulation of cholinergic receptors and/or monoamine receptors |
| 09/18/2003 | US20030176413 Polycyclic guanine derivative phosphodiesterase V inhibitors |
| 09/18/2003 | US20030176331 Having therapeutic, diagnostic, and preventative benefits, particularly as immunotoxins; for therapy of cancer |
| 09/18/2003 | US20030176317 Stabilization of hypoxia inducible factor (HIF) alpha |
| 09/18/2003 | US20030176315 Contacting latency-associated peptide- beta 1 (LAP- beta 1) or a functional variant thereof and integrin alpha v beta 3 or a functional variant thereof with test product under conditions that, in absence of test product, would permit interaction |
| 09/18/2003 | US20030175898 Isolated nucleic acids; immune response disease |
| 09/18/2003 | US20030175881 Nucleic acids encoding (poly) peptides having chips activity |
| 09/18/2003 | US20030175805 Comprises winglesslint 8D (Wnt-8D) polypeptides for treating asthma, nervous system, psychological, alzheimer, cancer, cardiomyopathies, lung and kidney disorders; wound healing agents; tissue engineering |
| 09/18/2003 | US20030175731 Hybrid immunomodulatory peptide and nucleotide sequences for treating allergies |
| 09/18/2003 | US20030175374 Oxidation resistance; anticancer agents, antiinflammatory agents; sunscreen agents |
| 09/18/2003 | US20030175309 Adjuvants for use in vaccines |
| 09/18/2003 | US20030175308 Adjuvants for use in vaccines |
| 09/18/2003 | US20030175299 Comprising lecithin, oils, amphiphilic surfactant and an antigen; for protecting pig against a Bordetella infections and/or a toxigenic Pasteuralla infections; stable oil-in-water emulsions, side effect reduction |
| 09/18/2003 | US20030175298 Comprising lecithin, oils, amphiphilic surfactant and an antigen; for protecting pig against a Bordetella infections and/or a toxigenic Pasteuralla infections |
| 09/18/2003 | US20030175269 Light and heavy chain peptides, used as antagonists of CD antigen or membrane proteins, for prophylaxis of autoimmune diseases |
| 09/18/2003 | US20030175258 Mixing shoots of Pinaceae plants with water and saccharides followed by spontaneous fermenting with yeasts to form remedies for allergic diseases; side effect reduction; for treatment of asthma, atopic dermatitis |
| 09/18/2003 | US20030175214 Free-flowing fine particle mixtures comprising carrier particles, active drug particles and stabilizer particles, for respiratory system disorders; medical equipment |
| 09/18/2003 | CA2482191A1 Spiro compounds with npy antagonistic activity |
| 09/18/2003 | CA2478958A1 Use of proton pump inhibitors for the treatment of airway disorders |
| 09/18/2003 | CA2478942A1 An optically active pyridine derivative and a medicament containing the same |
| 09/18/2003 | CA2478936A1 Monocyclic aroylpyridinones as antiinflammatory agents |
| 09/18/2003 | CA2478921A1 Novel chalcone derivatives and uses thereof |
| 09/18/2003 | CA2478897A1 Compounds capable of inhibiting immunocyte-related allergic immune reactions |
| 09/18/2003 | CA2478706A1 Oxo-azabicyclic compounds |
| 09/18/2003 | CA2478701A1 Derivatives of 4-(imidazol-5-yl)-2-(4-sulfoanilino) pyrimidine with cdk inhibitory activity |
| 09/18/2003 | CA2478652A1 Nitrosodiphenylamine derivatives and their pharmaceutical use against oxidative stress pathologies |
| 09/18/2003 | CA2478522A1 Novel curcuminoid-factor viia constructs as suppressors of tumor growth and angiogenesis |
| 09/18/2003 | CA2478317A1 Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate |
| 09/18/2003 | CA2478245A1 Treatment and prevention of inflammatory disorders |
| 09/18/2003 | CA2478065A1 Macrocyclic compounds useful as pharmaceuticals |
| 09/18/2003 | CA2476031A1 Novel substituted piperidines, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof |
| 09/18/2003 | CA2475738A1 Activated protein c formulations |
| 09/18/2003 | CA2474771A1 1-alpha-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses |
| 09/17/2003 | EP1344531A1 High molecular weight kininogen (HK) domain 5 derived peptides against thrombic diseases |
| 09/17/2003 | EP1344526A1 Preventives/ermedies for inflammatory airway diseases |
| 09/17/2003 | EP1344525A1 Aniline derivatives or salts thereof and cytokine production inhibitors containing the same |
| 09/17/2003 | EP1343900A2 Oxidoreductases |
| 09/17/2003 | EP1343895A2 Streptococcus pyogenes antigens and corresponding dna fragments |
| 09/17/2003 | EP1343888A2 Regulation of human chemokine-like receptor |
| 09/17/2003 | EP1343876A2 Modulators of activity of g-protein-coupled receptor kinases |
| 09/17/2003 | EP1343826A1 Polysaccharide compound having immune stimulating activity |
| 09/17/2003 | EP1343818A1 Modified tachykinin receptors |
| 09/17/2003 | EP1343786A1 Novel pyridine-substituted pyrazolopyridine derivatives |
| 09/17/2003 | EP1343784A2 Urea substituted imidazoquinoline ethers |
| 09/17/2003 | EP1343781A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 09/17/2003 | EP1343775A2 Piperazine derivatives |
| 09/17/2003 | EP1343769A1 Benzoylpyridazines |
| 09/17/2003 | EP1343759A1 Benzo(f) isoindol derivatives and their use as ep4 receptor ligands |
| 09/17/2003 | EP1343757A1 Indole derivatives |
| 09/17/2003 | EP1343751A2 Cyclic derivatives as modulators of chemokine receptor activity |
| 09/17/2003 | EP1343561A1 Serine protease inhibitors |
| 09/17/2003 | EP1343544A2 Uses of a medical device having a lubricious, nitric oxide-releasing coating for the therapy of vascular disorders |
| 09/17/2003 | EP1343521A2 Method for the stabilizing biomolecules (e.g. insulin) in liquid formulations |
| 09/17/2003 | EP1343506A1 Pharmaceutical formulation containing pyrazolo 4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives |
| 09/17/2003 | EP1343505A1 Cxcr3 antagonists |
| 09/17/2003 | EP1343492A2 Treatment of mucositis |
| 09/17/2003 | EP1343488A1 Treatment of statin side effects |
| 09/17/2003 | EP1244452B1 Carboxamide derivates of pyrrolidine and piperidine as urotensin-ii receptor antagonists |
| 09/17/2003 | EP1196411B1 Bradykinin b1 receptor antagonists |
| 09/17/2003 | EP1192163B1 DITHIEPINO 6,5-b]PYRIDINES, AND RELATED COMPOSITIONS AND METHODS |
| 09/17/2003 | EP1183241B1 Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them |
| 09/17/2003 | EP1147119B1 2,3-o-isoproylidene derivatives of monosaccharides as cell adhesion inhibitors |